Painreform Ltd (PRFX)

$3.02 -0.23 (-7.08%)
Market Cap 470,000.00
Revenue (ttm) 0.00
Net Income (ttm) -9.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 127,400
Avg Vol 4,008,719
Day's Range N/A - N/A
Shares Out 145,000.00
Stochastic %K 32%
Beta 0.64
Analysts Hold
Price Target $47.99

Latest News on PRFX

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

Dec 27, 2024, 8:30 AM EST - 21 days ago

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

Nov 20, 2024, 8:30 AM EST - 2 months ago

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Nov 7, 2024, 5:00 PM EST - 2 months ago

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

Sep 11, 2024, 8:30 AM EDT - 4 months ago

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

Sep 10, 2024, 9:46 AM EDT - 4 months ago

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

Aug 20, 2024, 8:30 AM EDT - 5 months ago

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

Aug 7, 2024, 10:00 AM EDT - 5 months ago

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

Aug 1, 2024, 8:30 AM EDT - 6 months ago

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

May 31, 2024, 4:15 PM EDT - 8 months ago

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

PainReform Provides Business Update for the First Quarter of 2024

May 15, 2024, 4:05 PM EDT - 8 months ago

PainReform Provides Business Update for the First Quarter of 2024

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

May 8, 2024, 8:30 AM EDT - 9 months ago

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

PainReform Announces Closing of $4 Million Public Offering

Apr 18, 2024, 2:19 PM EDT - 9 months ago

PainReform Announces Closing of $4 Million Public Offering

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

Apr 9, 2024, 9:00 AM EDT - 10 months ago

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Apr 2, 2024, 8:30 AM EDT - 10 months ago

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

PainReform Provides Year-End Business Update

Mar 1, 2024, 8:00 AM EST - 11 months ago

PainReform Provides Year-End Business Update

PainReform to Present at the Microcap Conference in Atlantic City

Jan 22, 2024, 8:30 AM EST - 1 year ago

PainReform to Present at the Microcap Conference in Atlantic City

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

Jan 3, 2024, 8:30 AM EST - 1 year ago

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

Dec 26, 2023, 6:00 PM EST - 1 year ago

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

PainReform Provides Business Update for the Third Quarter of 2023

Nov 15, 2023, 4:05 PM EST - 1 year ago

PainReform Provides Business Update for the Third Quarter of 2023

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

Sep 11, 2023, 8:30 AM EDT - 1 year ago

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

Sep 7, 2023, 10:00 AM EDT - 1 year ago

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

Sep 5, 2023, 8:30 AM EDT - 1 year ago

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

PainReform Provides Business Update for the Second Quarter of 2023

Aug 10, 2023, 4:05 PM EDT - 1 year ago

PainReform Provides Business Update for the Second Quarter of 2023

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

Jul 19, 2023, 9:00 AM EDT - 1 year ago

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

Jul 14, 2023, 2:35 PM EDT - 1 year ago

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

Jul 12, 2023, 9:05 AM EDT - 1 year ago

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

Jun 15, 2023, 8:30 AM EDT - 1 year ago

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

Jun 7, 2023, 4:30 PM EDT - 1 year ago

PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

PainReform Provides Business Update for the First Quarter of 2023

May 15, 2023, 4:45 PM EDT - 1 year ago

PainReform Provides Business Update for the First Quarter of 2023

PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

May 1, 2023, 8:30 AM EDT - 1 year ago

PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

Mar 28, 2023, 9:10 AM EDT - 1 year ago

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Mar 16, 2023, 8:00 AM EDT - 2 years ago

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Feb 7, 2023, 4:05 PM EST - 2 years ago

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

PainReform Provides Business Update for the Third Quarter of 2022

Nov 15, 2022, 8:30 AM EST - 2 years ago

PainReform Provides Business Update for the Third Quarter of 2022

PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 1, 2022, 8:00 AM EDT - 2 years ago

PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PainReform Provides Business Update for the Second Quarter of 2022

Aug 16, 2022, 8:05 AM EDT - 2 years ago

PainReform Provides Business Update for the Second Quarter of 2022

PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

Apr 12, 2022, 9:00 AM EDT - 3 years ago

PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

Mar 21, 2022, 9:25 AM EDT - 3 years ago

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022

Mar 17, 2022, 8:00 AM EDT - 3 years ago

PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022

PainReform CEO to Participate in the Benzinga All Access Event on December 16th

Dec 14, 2021, 8:30 AM EST - 3 years ago

PainReform CEO to Participate in the Benzinga All Access Event on December 16th

PainReform Provides Business Update for the Third Quarter of 2021

Nov 16, 2021, 8:00 AM EST - 3 years ago

PainReform Provides Business Update for the Third Quarter of 2021

PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

Oct 14, 2021, 8:30 AM EDT - 3 years ago

PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

PainReform Provides Business Update for the Second Quarter of 2021

Aug 16, 2021, 8:00 AM EDT - 3 years ago

PainReform Provides Business Update for the Second Quarter of 2021

PainReform Provides Business Update for the First Quarter of 2021

May 13, 2021, 8:15 AM EDT - 4 years ago

PainReform Provides Business Update for the First Quarter of 2021

PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

Mar 18, 2021, 9:15 AM EDT - 4 years ago

PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

Mar 11, 2021, 10:43 AM EST - 4 years ago

PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

PainReform Announces $6.0 Million Private Placement

Mar 8, 2021, 9:00 AM EST - 4 years ago

PainReform Announces $6.0 Million Private Placement

PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference

Jan 7, 2021, 8:30 AM EST - 4 years ago

PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference

PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

Jan 6, 2021, 8:30 AM EST - 4 years ago

PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations